Cleared Traditional

K792227 - MULTI-AD FLUID DISPENSING SYSTEM (FDA 510(k) Clearance)

Class I General Hospital device.

K792227 · National Patent Development Corp. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1979
Decision
45d
Days
Class 1
Risk

K792227 is an FDA 510(k) clearance for the MULTI-AD FLUID DISPENSING SYSTEM. Classified as Dispenser, Liquid Medication (product code KYX), Class I - General Controls.

Submitted by National Patent Development Corp. (Mchenry, US). The FDA issued a Cleared decision on December 20, 1979 after a review of 45 days - a notably fast clearance cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.6430 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all National Patent Development Corp. devices

Submission Details

510(k) Number K792227 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 05, 1979
Decision Date December 20, 1979
Days to Decision 45 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
83d faster than avg
Panel avg: 128d · This submission: 45d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code KYX Dispenser, Liquid Medication
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 880.6430
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.